Three recent articles highlight how shifting views of GLP-1 antiobesity medications. Dani Blum of the New York Times (gift link) reports on a large academic study finding that many people taking GLP-1 medications don’t have a medical indication such as diabetes or obesity. Users were more likely to be female, white, privately insured, and to have an eating disorder diagnosis. Mikala Jamison of The Atlantic (gift link) reports that weight loss companies are increasingly emphasizing benefits beyond weight loss, such as mental health. And Elaine Chen of STAT describes how Novo Nordisk, and increasingly other makers, are marketing GLP-1s as lifestyle products for “customers” rather than medicines for patients, with slogans like…
Insolvency Guardian
Insolvency Services & Bankruptcy Advice
